Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans

Drug Metabolism and Disposition

Volumn 38, Issue 11, 2010, Pages 2049-2059

  Christopher, Lisa J ^a   Hong, Haizheng ^a   Vakkalagadda, Blisse J ^a   Clemens, Pamela L ^a   Su, Hong ^a   Roongta, Vikram ^a   Allentoff, Alban ^a   Sun, Haojun ^a   Heller, Kevin ^a   Harbison, Christopher T ^a   Iyer, Ramaswamy A ^a   Humphreys, William G ^a   Wong, Tai ^a   Zhang, Steven ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 1 [[4 [(3 METHOXYPHENYL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 5 YL]METHYL] 3 PIPERIDINOL; BMS 690514; CARBON 14; GLUCURONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BMS-690514; CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; BILE; BLOOD SAMPLING; BREAST METASTASIS; CONTROLLED STUDY; DRUG EXCRETION; DRUG METABOLISM; FECES ANALYSIS; HUMAN; HUMAN EXPERIMENT; LUNG NON SMALL CELL CANCER; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; RADIOACTIVITY; URINALYSIS; ABSORPTION; ADOLESCENT; BIOTRANSFORMATION; BLOOD; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FECES; GENETICS; HYDROXYLATION; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION; TUMOR CELL LINE; URINE;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BILE; BIOTRANSFORMATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYLATION; MALE; OXIDATION-REDUCTION; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; TISSUE DISTRIBUTION; TRIAZINES; YOUNG ADULT;

EID: 78049354474     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034850     Document Type: Article

References (28)

1. Bahleda R, Felip E, Herbst RS, Hanna NH, Laurie SA, Shepherd FA, Armand JP, Sweeney CJ, Calvo-Aller E, and Soria JC (2008) Phase I multicenter trial of BMS-690514: safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 26 (15s):2564.
2. Bahleda R, Soria J, Harbison C, Park J, E. Felip, Hanna N, Laurie SA, Armand J, Shepherd FA, and Herbst R (2009) Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 27 (15s):abstr 8098.
3. Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, and Schellens JH (2007) Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 25:327-334. (Pubitemid 46944849)
4. Boddy AV, Sludden J, Griffin MJ, Garner C, Kendrick J, Mistry P, Dutreix C, Newell DR, and O'Brien SG (2007) Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res 13:4164-4169.
5. Bracco Diagnostics (2004) Kinevac® (sincalide for injection) prescribing information. Bracco Diagnostics, Princeton, NJ.
6. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, de Leon J, Koch WH, and Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542-551.
7. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364.
8. Currie LA (1968) Limits for qualitative detection and quantitative determination, application to radiochemistry. Anal Chem 40:586-593.
9. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, et al. (2007) A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67:6253-6262.
10. Desta Z, Wu GM, Morocho AM, and Flockhart DA (2002) The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30:336-343. (Pubitemid 34175027)
11. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246.
12. 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197-209.
13. 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5- yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30:823-830.
14. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, et al. (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555.
15. 14C]BMS-690514 after oral administration to rats, rabbits, and dogs. Drug Metab Dispos 38:1189-1201.
16. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, and Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158. (Pubitemid 37432975)
17. Lappin G and Garner RC (2004) Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem 378:356-364.
18. Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T, Christopher L, and Zhang H (2010) Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 99:3579-3593.
19. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234.
20. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550. (Pubitemid 44917502)
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
22. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203-220.
23. Tortora G, Ciardiello F, and Gasparini G (2008) Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5:521-530.
24. Vogel JS (1992) Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34:344-350.
25. Walker R (1973) The influence of gut micro-organisms on the metabolism of drugs and food additives. Proc Nutr Soc 32:73-78.
26. Wong T, Ayers M, and Emanuel S (2007) Inhibition of EGFR/HER2 signaling in tumor cells and VEGFR2 activity in tumor endothelium contribute to the preclinical anti-tumor activity of BMS-690514, in Proceedings of the AACR 98th Annual Meeting; 2007 Apr 14-18; Los Angeles, CA, Abstr 4007. American Association for Cancer Research, Philadelphia, PA.
27. Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT, et al. (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 12:6186-6193.
28. 14C]stavudine after oral administration to humans. Drug Metab Dispos 38:655-666.